ArticleScientific reports2017
Intracellular targeting of annexin A2 inhibits tumor cell adhesion, migration, and in vivo grafting.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 55 citations in OpenAlex.
- Annexin A2-dependent extracellular vesicle proteome modulates pre-metastatic stromal fibroblast behavior in triple-negative breast cancer.Cell communication and signaling : CCS · 2026Article
- Filamentous Phage for Therapeutic Applications in Non-Small Cell Lung Cancer and Brain Metastases: Recent Prospect.International journal of nanomedicine · 2026Review
- ANXA2 in hepatocellular carcinoma: orchestrating tumorigenesis, progression, and therapeutic resistance toward precision targeting.Journal of translational medicine · 2025Review
- Adaptive Proteomic Changes in Protein Metabolism and Mitochondrial Alterations Associated with Resistance to Trastuzumab and Pertuzumab Therapy in HER2-Positive Breast Cancer.International journal of molecular sciences · 2025Article
- A dynamic co-expression approach reveals Gins2 as a potential upstream modulator of HNSCC metastasis.Scientific reports · 2025Article
- Annexin A2: the feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment.Discover oncology · 2024Review
- Therapeutic targeting of voltage-gated sodium channel NaFrontiers in pharmacology · 2024Review
- Inhibition of the membrane repair protein annexin-A2 prevents tumor invasion and metastasis.Cellular and molecular life sciences : CMLS · 2023Article
- Diagnostic and Therapeutic Approaches for Glioblastoma and Neuroblastoma Cancers Using Chlorotoxin Nanoparticles.Cancers · 2023Review
- Collagen-I influences the post-translational regulation, binding partners and role of Annexin A2 in breast cancer progression.Frontiers in oncology · 2023Article
- Longitudinal single-cell transcriptomics reveals distinct patterns of recurrence in acute myeloid leukemia.Molecular cancer · 2022Article
- Antiphospholipid Antibodies and Lipids in Hematological Malignancies.International journal of molecular sciences · 2022Review
- Probable Mechanisms of Doxorubicin Antitumor Activity Enhancement by Ginsenoside Rh2.Molecules (Basel, Switzerland) · 2022Article
- Pathobiological functions and clinical implications of annexin dysregulation in human cancers.Frontiers in cell and developmental biology · 2022Review
- Epithelial-Mesenchymal Transition in colorectal cancer: Annexin A2 is caught in the crosshairs.Journal of cellular and molecular medicine · 2021Article
- The role of caveolae in endothelial dysfunction.Medical review (2021) · 2021Article
- Annexin Animal Models-From Fundamental Principles to Translational Research.International journal of molecular sciences · 2021Review
- Prognostic features of Annexin A2 expression in prostate cancer.Pathology · 2021Article
- Advances in cancer treatment: a new therapeutic target, Annexin A2.Journal of Cancer · 2021Review
- Analysis of the Expression and Prognostic Value of Annexin Family Proteins in Bladder Cancer.Frontiers in genetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 2 countries.
Funding
Abstract
Cytoskeletal-associated proteins play an active role in coordinating the adhesion and migration machinery in cancer progression. To identify functional protein networks and potential inhibitors, we screened an internalizing phage (iPhage) display library in tumor cells, and selected LGRFYAASG as a cytosol-targeting peptide. By affinity purification and mass spectrometry, intracellular annexin A2 was identified as the corresponding binding protein. Consistently, annexin A2 and a cell-internalizing, penetratin-fused version of the selected peptide (LGRFYAASG-pen) co-localized and specifically accumulated in the cytoplasm at the cell edges and cell-cell contacts. Functionally, tumor cells incubated with LGRFYAASG-pen showed disruption of filamentous actin, focal adhesions and caveolae-mediated membrane trafficking, resulting in impaired cell adhesion and migration in vitro. These effects were paralleled by a decrease in the phosphorylation of both focal adhesion kinase (Fak) and protein kinase B (Akt). Likewise, tumor cells pretreated with LGRFYAASG-pen exhibited an impaired capacity to colonize the lungs in vivo in several mouse models. Together, our findings demonstrate an unrecognized functional link between intracellular annexin A2 and tumor cell adhesion, migration and in vivo grafting. Moreover, this work uncovers a new peptide motif that binds to and inhibits intracellular annexin A2 as a candidate therapeutic lead for potential translation into clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.